GGrantIndex
← Leaderboards

Peter R Chai

Brigham And Women'S Hospital

$5,626,740
Attributed
$7,686,491
Total exposure
8
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4M · FY201825
$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,686,491 · 8

By mechanism

DP2$2,685,000 · 1
R44$1,548,668 · 1
K23$1,046,072 · 1
R21$962,126 · 2
R25$915,887 · 1
R34$269,468 · 1

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Innovation

Research focus

InnovationResponsePharmaceutical PreparationsSuccessCaringDesignSubstance Use DisorderEpidemicGrantBehavior TherapyCollaborationsMedicalPublic HealthPatternBaseInterestFeedbackMultidisciplinaryResearch PersonnelFundingParticipantIncidenceUnited StatesAdherence

Grant awards (21)

The ANTIDOTE Institute- Advancing New Toxicology Investigators in Drug abuse and Original Translational research Efforts$314,491
R25 · FY2025 · DA
Harmonized Healing: Personalized Music Interventions to Address Chronic Pain in People Living with HIV$269,468
R34 · FY2025 · AT · contact PI
The ANTIDOTE Institute- Advancing New Toxicology Investigators in Drug abuse and Original Translational research Efforts$299,403
R25 · FY2024 · DA
Ketamine for the treatment for opioid use disorder and suicidal ideation in the emergency department$268,500
R21 · FY2024 · DA
The ANTIDOTE Institute- Advancing New Toxicology Investigators in Drug abuse and Original Translational research Efforts$301,993
R25 · FY2023 · DA
Ketamine for the treatment for opioid use disorder and suicidal ideation in the emergency department$223,750
R21 · FY2023 · DA
Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trial$212,563
R21 · FY2023 · AA
Smart Steps: A context-aware adherence intervention to improve PrEP adherence among men who have sex with men (MSM) with substance use disorder$2,685,000
DP2 · FY2022 · DA · contact PI
A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities$361,518
R44 · FY2022 · DA
ID-Cap System: Next generation ingestible sensors for medication adherence measurement$259,270
R43 · FY2022 · NR
Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trial$257,313
R21 · FY2022 · AA
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users$195,528
K23 · FY2022 · DA · contact PI
A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities$174,937
R44 · FY2022 · DA
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users$67,491
K23 · FY2022 · DA · contact PI
A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities$549,080
R44 · FY2021 · DA
A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities$250,806
R44 · FY2021 · DA
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users$195,568
K23 · FY2021 · DA · contact PI
A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities$212,327
R44 · FY2020 · DA
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users$195,568
K23 · FY2020 · DA · contact PI
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users$195,957
K23 · FY2019 · DA · contact PI
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users$195,960
K23 · FY2018 · DA · contact PI